Aiming to Carve Out a Share of a Niche Market, ABI Rolls Out miRNA Assays | GenomeWeb

Applied Biosystems last week launched its TaqMan microRNA assays, thrusting the firm into an emerging niche market that has yet to establish a dominant player.

ABI is banking on its broad market reach, reputation of TaqMan, and currently installed instrument base to establish a presence in the microRNA market. In addition, the firm should be able to take advantage of its collaboration with noted genetics and microRNA researcher Victor Ambros of Dartmouth University to raise its profile among researchers in the field.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.